The price take-down is a last desperate attempt before the conference call to shake the confidence of investors who do not understand how good our clinical trial results are.

Unlike most other small biotechs, we have multiple completely different drugs in development. Any one of them having good results in their current phase would justify a price of 10-20/share.

Why else do you think such a huge effort is being made to try to scare people out of this stock?